2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology
Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO Global Oncology 2021, 7: go.20.00589. PMID: 33529077, PMCID: PMC8081548, DOI: 10.1200/go.20.00589.Peer-Reviewed Original ResearchConceptsMedical oncologistsCOVID-19 positive patientsCOVID-19 outbreakUse of telemedicineClinical trial activityAffected modalityPalliative treatmentOncology unitLong-term impactNational registryPostacute phaseClinical activityMultidisciplinary meetingOncologic activityLocal registryHealthcare staffTreatment adaptationPatientsEarly cessationTrial activityHealthcare systemCOVID-19 pandemicOncologistsRegistrySignificant reduction
2017
Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer
Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, DiGiovanna MP, Silber ALM, Adelson K, Pusztai L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657377, DOI: 10.1200/cci.17.00015.Peer-Reviewed Original ResearchConceptsAdverse effectsEndocrine therapyClinical trialsBreast cancerFrequency of AEsMedication-related adverse effectsTherapy-related adverse effectsBidirectional Text MessagingEndocrine therapy adherenceAdjuvant endocrine therapyMajority of patientsMedical record reviewSevere adverse effectsText message systemConsecutive patientsVaginal symptomsRecord reviewHot flashesTherapy adherenceClinic nursesHistorical controlsPatient acceptanceProvider teamGeneral populationPatients